Other formats:
BibTeX
LaTeX
RIS
@proceedings{60398,
author = {Hlaváč, Kryštof and Ondrišová, Laura and Šeda, Václav and Pavelková, Petra and Hoferková, Eva and Filip, Daniel and Mráz, Marek},
booktitle = {XXII. Interdisciplinary Meeting of Young Life Scientists, Milovy},
keywords = {Chronic lymphocytic leukemia; BTK inhibitor; ibrutinib; PI3K inhibitor; idelalisib;},
language = {eng},
title = {Molecular response of chronic lymphocytic leukemia cells to targeted therapy.},
url = {http://www.ccsss.cz/index.php/ccsss/issue/view/38},
year = {2023}
}
TY - CONF
ID - 60398
AU - Hlaváč, Kryštof - Ondrišová, Laura - Šeda, Václav - Pavelková, Petra - Hoferková, Eva - Filip, Daniel - Mráz, Marek
PY - 2023
TI - Molecular response of chronic lymphocytic leukemia cells to targeted therapy.
KW - Chronic lymphocytic leukemia
KW - BTK inhibitor
KW - ibrutinib
KW - PI3K inhibitor
KW - idelalisib;
UR - http://www.ccsss.cz/index.php/ccsss/issue/view/38
N2 - amp;Run assay, an alternative to ChIPseq, in the MEC1 cell line, to characterize genes directly regulated by this transcription factor. Apart from the regulation of the BCR signaling pathway, we noticed its potential in response to other drugs such as the BH3 mimetic (BCL2 inhibitor) venetoclax that has been recently approved for CLL therapy. Altogether, we thoroughly describe particular changes in CLL transcriptome, that provide increase in survival of leukemic cells during the BCR inhibitors therapy in both primary CLL cells and cell lines. Based on these results, we further suggest a rational combinatorial treatment of ibrutinib/idelalisib with an inhibitor targeting the transcription factor as a potential therapeutic strategy to eliminate mechanism of adaptation to BCR inhibitors.
ER -
HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Petra PAVELKOVÁ, Eva HOFERKOVÁ, Daniel FILIP and Marek MRÁZ. Molecular response of chronic lymphocytic leukemia cells to targeted therapy. In \textit{XXII. Interdisciplinary Meeting of Young Life Scientists, Milovy}. 2023.
|
